Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America (Q36382134)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America (English)

1 reference

Europe PubMed Central

13 August 2017

infectious diseases

1 reference

based on heuristic

inferred from title

author name string

George H Talbot

1

1 reference

Europe PubMed Central

13 August 2017

John Bradley

2

1 reference

Europe PubMed Central

13 August 2017

John E Edwards

3

1 reference

Europe PubMed Central

13 August 2017

David Gilbert

4

1 reference

Europe PubMed Central

13 August 2017

Michael Scheld

5

1 reference

Europe PubMed Central

13 August 2017

John G Bartlett

6

1 reference

Europe PubMed Central

13 August 2017

Antimicrobial Availability Task Force of the Infectious Diseases Society of America

7

1 reference

Europe PubMed Central

13 August 2017

language of work or name

0 references

publication date

25 January 2005

1 reference

Europe PubMed Central

13 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

13 August 2017

42

1 reference

Europe PubMed Central

13 August 2017

657-668

1 reference

Europe PubMed Central

13 August 2017

5

1 reference

Europe PubMed Central

13 August 2017

Antimicrobial resistance trends and outbreak frequency in United States hospitals

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Trends in antimicrobial drug development: implications for the future

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Lack of development of new antimicrobial drugs: a potential serious threat to public health.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

The antibiotic pipeline--challenges, costs, and values

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Why is big Pharma getting out of antibacterial drug discovery?

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Development of drugs for antimicrobial-resistant pathogens

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Antimicrobial drug development--the past, the present, and the future

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Taking inventory: antibacterial agents currently at or beyond phase 1.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Cephalosporins in clinical development

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

New advances in antibiotic development and discovery

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Multidrug-resistant Acinetobacter extremity infections in soldiers

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Atypical infections in tsunami survivors

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (199

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Recent trends in the epidemiology of invasive mycoses

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Aspergillosis in "nonimmunocompromised" critically ill patients

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Update on antifungal treatment of invasive Candida and Aspergillus infections

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Caspofungin: first approved agent in a new class of antifungals

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Outbreak of multi-resistant Klebsiella oxytoca involving strains with extended-spectrum beta-lactamases and strains with extended-spectrum activity of the chromosomal beta-lactamase.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

The new beta-lactamases.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Vancomycin-resistant enterococci among chronic hemodialysis patients: a prospective study of acquisition

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Health and economic outcomes of vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Pseudomonas aeruginosa pneumonia

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Pseudomonas aeruginosa infections in the neonatal intensive care unit

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Pulmonary infections in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Metallo-beta-lactamases: the quiet before the storm?

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Efflux-mediated multiresistance in Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems?

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Methicillin-resistant-Staphylococcus aureus hospitalizations, United States

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?

1 reference

https://api.crossref.org/works/10.1086%2F499819

21 January 2018

Identifiers

1 reference

Europe PubMed Central

13 August 2017

1 reference

Europe PubMed Central

13 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36382134&oldid=1628562424"